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Abstract
The Hatch-Waxman Act provides pharmaceutical manufacturers an incentive to introduce
reformulations of existing products about to lose patent protection in order to extend marketing
exclusivity and maintain high prices. Antidepressant reformulations are particularly common. To
determine whether antidepressant reformulation use confers benefits, we examine who uses
reformulations, and compare medication continuation and the likelihood of receiving guideline-
consistent pharmacotherapy duration among reformulation and original formulation users. We find
some evidence of benefit for subgroups of antidepressant users, although benefits vary across
reformulations.
With generic entry reducing market share for top-selling brand drugs in a number of classes,
many pharmaceutical manufacturers are reformulating their existing products in an attempt to
extend the life cycle of these drugs.1 Under the Hatch-Waxman Act of 1984, manufacturers
can obtain three to five additional years of market exclusivity for a reformulation.2
Consequently, manufacturers have an incentive to shift demand for an original formulation
that will soon lose patent protection to a reformulation of the same drug.3
Critics of the pharmaceutical industry assert that manufacturers devote too many resources to
developing products like “me-too” drugs and reformulations that are only marginally different
from existing products, and thus of limited value to society, rather than to developing
breakthrough drugs.4 In contrast, others argue that reformulations represent advances in safety
or efficacy and result in increased patient compliance.5
Reformulations are particularly common among psychiatric medications. These
reformulations often involve less frequent dosing, more controlled release (i.e., the active
ingredient is released more gradually during the day), or easier-to-administer dosing (e.g., a
tablet that dissolves on the tongue) than the originator products. In theory, reformulations could
be particularly useful for some patients with mental illness, such as patients for whom the
illness itself limits their ability to adhere to a medication regimen or patients who experience
intolerable side effects from existing medications. However, little is known about the benefits
of reformulations as they are used in real-world settings.
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To determine if benefits exist, we examined use of several antidepressant reformulations
among Florida Medicaid enrollees. Specifically, we identified characteristics of reformulation
users, examined whether reformulation users with major depression are more likely to receive
guideline-consistent antidepressant duration than original formulation users, and examined
whether reformulation users continue taking antidepressants longer than original formulation
users.
Antidepressant Reformulations
We studied six reformulated antidepressants: two selective serotonin reuptake inhibitors
(SSRIs) (Paxil CR and Lexapro), and four others (Effexor XR, Remeron Soltab, Wellbutrin
SR, and Wellbutrin XL). Four are extended-/controlled-release formulations (Effexor XR,
Paxil CR, Wellbutrin SR, and Wellbutrin XL). This type of reformulation would not be
expected to have different biologic activity than its original formulation, but could have reduced
side effects or, in some cases, require less frequent dosing.6 Remeron Soltab is a dissolvable
tablet targeted at patients who have difficulty swallowing. Although potentially easier to
administer than standard tablets, Remeron Soltab would not be expected to have different
biologic properties or side effects than Remeron once ingested. Lexapro is a different type of
reformulation. Celexa is a mixture of two mirror-image molecules (isomers) - one that
contributes to its antidepressant effect and one that doesn’t. In creating Lexapro, the
manufacturer removed the molecule that doesn’t contribute to Celexa’s antidepressant effect,
leaving only the molecule that does. This single-isomer drug could, in theory, be more potent
or faster-acting, so one may find larger differences in either efficacy or tolerance between
Lexapro and Celexa than between the other reformulations and their original forms.7
Although the manufacturers’ marginal costs of producing reformulations are likely similar to
the marginal production costs for the original formulations, prices paid by payers are often
considerably higher for reformulations than for generic versions of the original products. For
example, online drugstore.com shoppers paid $106.99 for a 30-day supply of the minimally-
therapeutic dose of Paxil CR versus $13.99 for a similar dose of generic paroxetine as of January
2009.8
Clinical trial evidence on whether reformulations have greater efficacy or tolerability than the
original formulations is relatively sparse and mixed at best.9 Among the six reformulations we
assessed, even the most studied (Lexapro) has only a handful of trials comparing it to Celexa.
Most studies for the six reformulations show little or no difference in efficacy. For those that
do (a subset of the studies of Lexapro vs. Celexa; no studies of the other reformulations find
efficacy differences), the difference in symptom reduction typically is relatively small, and
some have argued not clinically meaningful.10 Results on tolerability differences are also
mixed. Some studies show no difference, while a small number find that a particular
reformulation may be associated with somewhat less severe side effects than its original
formulation, particularly in the early phases of treatment. In theory, greater tolerability early
in treatment could increase the likelihood that some patients continue taking the medication
until they reach therapeutic durations, although these studies did not document differences in
dropout rates due to side effects. Regardless of whether reformulations show greater efficacy
or tolerability in carefully-selected populations enrolled in clinical trials, understanding
whether there are any benefits from reformulation use requires measuring benefits for all users,
not just clinical trial participants.
Methods
Using eligibility and claims data over the period July 1996 through June 2005, we first
identified characteristics associated with use of a specific reformulation.11 Then, we quantified
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patient benefit in two ways. Our primary measure was the likelihood of receiving antidepressant
therapy for a duration consistent with professional guidelines for acute phase treatment of major
depression.12 Receipt of such care has been documented to be predictive of significant
improvement in mental health outcomes.13 To determine whether reformulation users are more
likely to get appropriate pharmacotherapy, we compared the likelihood of receiving guideline-
consistent duration among individuals using a given reformulation and individuals using its
original formulation. We also examined an intermediate measure of benefit - medication
continuation. Professional guidelines for mental health conditions other than major depression
are not specific about appropriate antidepressant duration. However, the clinical literature
suggests that there can be delays of several weeks or longer for an antidepressant to reach its
maximum therapeutic effect, and antidepressant continuation up to some minimal duration is
generally viewed as associated with positive outcomes like symptom reduction.14 Thus, we
compared time to discontinuation among individuals using a given reformulation and
individuals using its original formulation. If reformulations have greater tolerability, efficacy,
or quicker onset of therapeutic benefit, then discontinuation rates should be lower.
We excluded individuals who were under age 18 and individuals for whom we were unable to
observe all pharmacy and medical data (e.g., HMO enrollees, Qualified Medicare
Beneficiaries). Additional detail on each of the three analyses is available in an Appendix.
Who Uses Reformulations?
To identify characteristics of reformulation users, we estimated a set of logit models (one for
each reformulation) of the probability of filling a prescription for a given product in the year
after its introduction among “current” antidepressant users, defined as those who filled any
antidepressant prescriptions in the 90 days before the reformulation’s introduction.15
The models included the following covariates: age and age-squared; sex; race/ethnicity (black,
Hispanic, white, other); eligibility category (Supplemental Security Income (SSI), Aid to
Families with Dependent Children (AFDC), dual eligible, other); mental health/substance
abuse (MH/SA) diagnoses in the six months before the observational window (anxiety but no
depression, depression but no anxiety, both depression and anxiety, bipolar disorder,
schizophrenia, other MH diagnoses, no MH diagnosis, SA disorder); presence of a diagnosis
associated with difficulty swallowing; outpatient encounter with a psychiatrist during the past
six months; use of inpatient MH/SA care in the past six months; nursing home residence during
the observational period; number of months enrolled after reformulation introduction; and
whether the patient had been taking the original formulation (e.g., equals “1” in Paxil CR model
if the patient had been taking Paxil).
Guideline-consistent Antidepressant Duration for Major Depression
As our measure of guideline-consistent duration, we used the HEDIS measure for acute phase
antidepressant management for major depression.16 According to this measure, an individual
with a new episode of major depression (i.e., no recent depression diagnoses or antidepressants)
who receives an antidepressant should remain on the medication throughout the acute phase
of treatment (approximately first 12 weeks). To allow for delays in filling prescriptions, we
considered individuals who received at least 84 days of medication in the first 114 days after
the episode began to have met the guideline duration.
To compare the likelihood of receiving guideline-consistent duration among reformulation
users and original formulation users, we created matched pairs of similar individuals using
propensity score matching.17 We first identified individuals who initiated an episode of major
depression in the two-year period after a reformulation was introduced and who used that
reformulation. We then matched them to two other groups: 1) individuals with a new episode
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of major depression during the same period who used the original formulation
(“contemporaneous” original formulation users); and 2) individuals with a new episode of
major depression just before the reformulation was introduced who used the original
formulation (“non-contemporaneous” users of the original).18 We created the non-
contemporaneous comparison group to address possible selection effects. For example, when
both Celexa and Lexapro are available, there may be unobservable differences between
individuals who take Lexapro and individuals who take Celexa. Therefore, we also compared
Lexapro users to Celexa users in the period before patients had a choice between the two
products.
The propensity score models controlled for the covariates from the logit models described
above, as well as region, number of other medication classes used in the previous year (≤4,
5-8, ≥9), and any cognitive deficit diagnosis in the previous six months.19 Using the matched
pairs, we estimated a logit model for the probability of receiving guideline-consistent duration
for each comparison (e.g., Paxil CR users and non-contemporaneous Paxil users). Because
Wellbutrin SR, Effexor XR, and Wellbutrin XL were introduced either at the very beginning
or end of our study period, we could not study these products due to an insufficient
observational period. We were unable to study Remeron Soltab because the number of
Remeron Soltab and Remeron users with a new episode of major depression was too small.
Time to Discontinuation
To compare time to antidepressant discontinuation among reformulations users and original
formulations users, we created a second set of propensity score matches. All new antidepressant
users (i.e., those who hadn’t filled any antidepressant prescriptions in the previous 90 days),
regardless of diagnosis, were eligible for matching. Using the matched pairs, we estimated
Kaplan-Meier curves of time to discontinuation.
Results
Over the ten-year study period, characteristics of antidepressant users remained relatively
stable (Exhibit 1). Approximately 40% were over age 65. Most were white (58-62%), while
12% were black and 6-10% were Hispanic. Almost half were dually-eligible for Medicare.
Over two-thirds (69%-72%) had no MH diagnosis in the past six months and most (77%-83%)
had not seen a psychiatrist during the past six months.
Who Uses Reformulations?
Reformulation use was generally less common among younger enrollees, men, blacks (relative
to whites), and SSI beneficiaries (relative to dual eligibles) (Exhibit 2). Original formulation
users were more likely to fill a prescription for the reformulation once it was available than
people who had been using a different drug.
Individuals who had seen a psychiatrist were more likely to receive a reformulation. Patients
diagnosed with both anxiety and depression were more likely to get an SSRI reformulation but
not more likely to get another reformulation.20 Individuals with no recorded MH diagnosis,
generally more common among patients treated in primary care than in the specialty MH sector,
were less likely to receive four of the reformulations (no significant difference for the other
two). Patients with recent MH/SA inpatient use were more likely to get two of the
reformulations (no significant difference for the others). Individuals likely to have difficulty
swallowing were more likely to use Remeron Soltab but not more likely to use the others (all
pills that must be swallowed).
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Guideline-consistent Antidepressant Duration for Major Depression
In both the non-contemporaneous and contemporaneous comparisons, Lexapro and Paxil CR
patients with major depression were more likely to receive guideline-consistent duration than
similar patients using the original formulation (Exhibit 3). For example, 46% of Lexapro users
versus 36% of non-contemporaneous Celexa users received guideline-consistent duration. The
differences were significant for all comparisons except Paxil CR/non-contemporaneous Paxil,
which was of borderline significance.
Time to Discontinuation
Celexa users were more likely to discontinue earlier than Lexapro users (Exhibit 4). Median
days to discontinuation was 91 for Lexapro users vs. 64 for Celexa users in the non-
contemporaneous comparison, and 76 vs. 61 in the contemporaneous comparison. The curves
diverged around thirty days after medication initiation, suggesting that Lexapro users were
more likely to refill their initial prescription than Celexa users.
For Paxil CR vs. Paxil, there was a statistically-significant, although smaller, difference in time
to discontinuation. For example, median days to discontinuation was 64 for Paxil CR users vs.
61 for non-contemporaneous Paxil users. Again, the curves diverged around thirty days after
initiation. For Remeron Soltab vs. Remeron, there was no statistically-significant difference
for the non-contemporaneous comparison and only a very small significant difference for the
contemporaneous comparison.
Conclusions
Using duration-based measures, we found some evidence of benefit associated with
reformulation use, although our findings suggest that all reformulations are not created equal.
Lexapro users, on average, continued longer than Celexa users, and Paxil CR users continued
longer than Paxil users. The difference was larger for Lexapro vs. Celexa, which might be
expected since Lexapro is more different from Celexa than Paxil CR is from Paxil. There was
no notable difference for Remeron Soltab vs. Remeron. However, given that a dissolvable
tablet’s primary potential benefit may be ease of administration as opposed to reduced side
effects or improved efficacy, this result may not be surprising.
Reformulation benefits may be unequal across subgroups of antidepressant users. Given the
relative clarity of the major depression treatment guidelines on appropriate duration of
pharmacotherapy, our findings that Lexapro and Paxil CR users with major depression were
more likely to receive guideline-consistent antidepressant duration compared to similar users
of the original formulations suggest positive benefit associated with reformulation use for this
population. The implications of our results on time to discontinuation for the entire population
of reformulation users (not just those with major depression) are less clear, however. Longer
use may not be better for all patients, and the indications for antidepressant use are unclear for
the approximately two-thirds of users with no recorded MH diagnosis in the previous six
months. Some may be individuals with episodic major depression; others may be receiving the
reformulation for depression or anxiety symptoms but no clear diagnosis, or even for chronic
pain.
Given that we could only document clear benefits for individuals with a diagnosis of major
depression (88-91% of antidepressant users in our population), should we expect all
reformulation users to derive equal benefit? One could argue that reformulation users are
revealing their preference for the reformulation by their willingness to pay the additional costs
associated with its use. However, Medicaid recipients typically pay either a nominal or no
copayment for each prescription filled and often face either no differential cost or only a very
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small one if they select a reformulation over its original formulation, so their choice of a
reformulation does not involve weighing the full costs and benefits.21 Also, some patients and
their physicians may be influenced by manufacturer promotional efforts to select a
reformulation even though the expected benefits may not be greater for the patient.
It is also possible that physicians may be doing a careful job of matching reformulations to
those patients likely to get greater benefit from them, and thus some potential users would not
derive the benefits we documented. We found that patients with difficulty swallowing were
more likely to get Remeron Soltab but not the reformulations that must be swallowed. Patients
with comorbid depression and anxiety, and thus perhaps more complicated courses of illness,
were more likely to use an SSRI reformulation. Reformulation use was more common among
patients who recently saw a psychiatrist or were hospitalized, who also may be more likely to
have relatively severe or complicated conditions, although it is also possible that psychiatrists
are more likely to prescribe new medications or are subject to a greater level of manufacturer
promotion. While our results may be somewhat suggestive of some level of matching, we are
unable to determine the extent to which good matches are being made as opposed to inefficient
matches.
Alternatively, it is also possible that doctors who prescribe reformulations are “better” doctors
who may be more successful at convincing their patients to continue an antidepressant until
guideline-consistent durations are reached. Our models control for whether the enrollee is being
treated by a psychiatrist, but our data do not allow us to distinguish effects of the individual
provider or other provider-level characteristics.
Given that we found some evidence of benefit, at least for patients with major depression, how
might these benefits compare to the costs of the medications from a societal perspective? Is
their value sufficient to warrant their development? According to economic theory, long-run
societal marginal costs for reformulations approximate their marginal costs of production (i.e.,
the manufacturing costs).22 In most cases, a reformulation’s marginal production costs are
likely to be similar to those for the original formulation (e.g., the marginal costs of producing
one tablet of Paxil are probably similar to the marginal costs of producing one tablet of Paxil
CR). The additional R&D costs likely depend on the novelty of the reformulation, although in
most cases R&D costs should be lower than for developing an entirely new drug. Also, testing
requirements are typically less extensive for reformulations than for new molecules.23
If the societal marginal costs are in fact relatively low, a reformulation that could show even
very limited benefits would add value from a societal perspective. If so, the Hatch-Waxman
Act provisions governing reformulations may introduce inefficiencies into the market. The law
provides incentives for firms to delay reformulation introduction until patent expiration
approaches for the original formulation in order to take maximum advantage of the exclusivity
extension.24 As a result, release of reformulations for which there is some value is delayed
from society’s perspective, and policymakers may wish to reconsider the Hatch-Waxman
provisions governing reformulations.
From a payer’s perspective, the value associated with reformulations is less clear. If the
government (acting as a payer for Medicare and Medicaid) compared the incremental costs
and benefits of reformulations relative to original formulations or other similar drugs (for
example, as NICE might do in the UK), it is unclear whether the magnitude of benefits we
documented would be sufficient to warrant a decision to cover the reformulation given the
current differences in prices that payers typically face. Manufacturers might be willing to
negotiate lower prices if the drug might not be covered (as they have done in some cases in the
UK) or the government could attempt to target reformulations to those with higher marginal
benefits (e.g., Soltab only for those with documented difficulty swallowing) using tools like
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prior authorization. For employers, coverage of reformulations will depend in part on the labor
market and the offerings of similar employers. Payers might also be more willing to cover
reformulations if their use offset other health care expenditures, although there is no such
evidence to date on offsets.
Several limitations should be noted. First, using claims data to understand medication
utilization allows one to study use in a large population treated in real-world settings; however,
clinical information is somewhat limited, and MH diagnoses can be undercoded. Claims data
do not capture medications not reimbursed by Medicaid, such as free samples. Second,
propensity score matching only addresses differences in observable characteristics. There may
be unmeasured characteristics that influence selection of one drug or another. Our approach
of comparing reformulation users with both contemporaneous and non-contemporaneous users
of original formulations helps to address this potential selection, but may not resolve it entirely.
Third, we focus on two measures of benefit that are typically associated with improved mental
health outcomes. We are unable to capture all potential benefits that could result, such as
increased labor market productivity or ease of administration. Fourth, we use data from a single
state Medicaid program. Utilization patterns for reformulations may differ in privately-insured
or non-dual-eligible Medicare populations.
Our results provide some evidence of benefit for reformulations, although the benefit varies
across reformulations and may differ by diagnosis. We also documented racial disparities in
receipt of reformulated antidepressants, as blacks were significantly less likely to receive
reformulations than whites.25 The fact that some of these medications confer benefits for at
least certain subpopulations makes these disparities troubling and highlights the need for
research to understand the factors driving them.
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Exhibit 1
Characteristics of Antidepressant Users, 1997-2004
Characteristics 1997 2001 2004
Number of Users 115,683 161,260 203,274
Female 73% 72% 73%
Race
 White 62% 60% 58%
 Black 12% 12% 12%
 Hispanic 6% 8% 10%
 Other 20% 20% 20%
Age
 18-25 3% 4% 4%
 26-35 11% 10% 10%
 36-45 17% 17% 15%
 46-55 13% 16% 16%
 56-64 13% 14% 15%
 65+ 43% 40% 40%
Eligibility Status
 AFDC 8% 8% 8%
 SSI 25% 24% 22%
 Dual 48% 46% 45%
 Other 18% 22% 25%
Mental Health Dx
 Depression − all 20% 19% 17%
  Major depression 12% 11% 9%
 Anxiety 5% 6% 6%
 Depression + Anxiety 2% 2% 2%
 No Mental Health Dx 69% 70% 72%
 Substance Use 4% 4% 3%
Difficulty Swallowing 5% 5% 5%
Nursing Home Resident 10% 11% 11%
Seen Psychiatrist 23% 21% 17%
MHSA Inpatient Use 3% 3% 2%
# Other Medication Classes
 ≤4 39% 33% 30%
 5-8 37% 36% 33%
 >8 23% 31% 37%
Note: The number of other medication classes refers to the number of medication classes used besides antidepressants.
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